201 related articles for article (PubMed ID: 27132755)
1. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Lindner LM; Marasciulo AC; Farias MR; Grohs GE
Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
8. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
Essock SM; Frisman LK; Covell NH; Hargreaves WA
Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
12. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
[TBL] [Abstract][Full Text] [Related]
13. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs.
Rosenheck R; Doyle J; Leslie D; Fontana A
Schizophr Bull; 2003; 29(1):81-93. PubMed ID: 12908663
[TBL] [Abstract][Full Text] [Related]
14. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
Amin S
Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
[TBL] [Abstract][Full Text] [Related]
16. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
Gau SS; Chung CH; Gau CS
J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
[TBL] [Abstract][Full Text] [Related]
17. Clozapine and hospitalization.
Rosenheck R; Charney D; Cramer J
Psychiatr Serv; 1999 Jan; 50(1):114-6. PubMed ID: 9890595
[No Abstract] [Full Text] [Related]
18. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics.
Tilden D; Aristides M; Meddis D; Burns T
Clin Ther; 2002 Oct; 24(10):1648-67. PubMed ID: 12462294
[TBL] [Abstract][Full Text] [Related]
19. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
